TransCode Therapeutics Inc (RNAZ) USD0.0001
Sell:$8.54Buy:$9.00
$0.32
(3.50%)
- This stock can be held in a
Stocks and Shares ISA$0.32
(3.50%)$0.32
(3.50%)Company Information
About this company
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is focused on defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a well-documented biomarker of metastasis. It is also developing a portfolio of other RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers. Its preclinical programs include TTX-siPDL1, is an siRNA-based modulator of programmed death-ligand 1, or PD-L1, TTX-RIGA, is an RNA-based agonist of the retinoic acid-inducible gene I, or RIG-I, targeting activation of innate immunity in the tumor microenvironment and TTX-siMYC is a siRNA-based inhibitor of c-MYC.
Key people
Key facts
- EPICRNAZ
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS89357L5012
- Market cap$7.61m
- Employees7
- Shares in issue833,620.00
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.